Allergan Ceo, Brent Saunders, interviewed by  CNBC’s Meg Tirrell, talked about the expectation for 2017.

He has recalled how much went on for Allergan in 2016 from the merge with Pfizer to the sell of Actavis Generic Allergan’s generics unit, to Teva, saying the the company had  probably the most profound transformation of any pharmaceutical company in the past ten years.

He admitted also that the stock market has been an disappointment and for 2017 the aim is to deliver better sales objectives and advance on the pipeline.

He underlined that the company has six drugs reaching phase-3 in 2017, “all of which have blockbuster potential”, that’s why 2017 for Allergan could be an exciting and promising year.

At the end of the interview Brent Saunders says he is encouraged and we it will be seen a very constrictive movement by the entire industry.

Watch the full interview on CNBC website